CTLA4 and neoplasm: Furthermore, dual ICB, which targets both PD-1 and CTLA-4 at the same time, has shown greater efficacy than single ICB in patients with metastatic NSCLC and melanoma (40, 43), and is more effective in melanoma patients with smaller baseline tumor diameters (50).